Arcutis Biotherapeutics (ARQT) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free ARQT Stock Alerts $8.02 +0.03 (+0.38%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineArcutis Biotherapeutics (ARQT) Set to Announce Earnings on Tuesdaymarketbeat.com - May 7 at 9:21 AMArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.7%americanbankingnews.com - May 5 at 6:02 AMArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - May 4 at 7:06 PMArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.7% marketbeat.com - May 3 at 10:51 PMArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 3 at 4:00 PMArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.9%marketbeat.com - May 1 at 4:49 PMabrdn plc Acquires New Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)marketbeat.com - May 1 at 5:01 AMFederated Hermes Inc. Buys 461,469 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)marketbeat.com - April 30 at 4:46 AMArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Rating of "Moderate Buy" by Analystsamericanbankingnews.com - April 30 at 4:16 AMArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024globenewswire.com - April 29 at 4:00 PMArcutis Biotherapeutics Sees Unusually High Options Volume (NASDAQ:ARQT)marketbeat.com - April 26 at 4:05 PMIndustry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecastsfinance.yahoo.com - April 26 at 8:14 AMJennison Associates LLC Purchases 4,633,907 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)marketbeat.com - April 25 at 7:27 AMAnalysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)markets.businessinsider.com - April 22 at 7:21 AMArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 4.2%marketbeat.com - April 18 at 1:56 PMDekaBank Deutsche Girozentrale Invests $462,000 in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)marketbeat.com - April 16 at 5:03 AMArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Updatemarketbeat.com - April 13 at 12:23 PMArcutis Biotherapeutics Inc Ordinary Shares ARQTmorningstar.com - April 12 at 3:06 PMArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8%marketbeat.com - April 12 at 12:46 PMAnalysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)markets.businessinsider.com - April 12 at 10:06 AMEvaluating Arcutis Biotherapeutics: Insights From 5 Financial Analystsmarkets.businessinsider.com - April 12 at 10:06 AMArcutis Biotherapeutics' (ARQT) "Buy" Rating Reiterated at Needham & Company LLCmarketbeat.com - April 12 at 8:14 AMArcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officerfinanznachrichten.de - April 10 at 9:22 PMArcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFOmarkets.businessinsider.com - April 10 at 4:21 PMTraders Buy Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT)marketbeat.com - April 10 at 1:38 PMArcutis Biotherapeutics Names David Topper as Finance Chiefmarketwatch.com - April 10 at 8:51 AMBuy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside Potentialmarkets.businessinsider.com - April 10 at 8:51 AMArcutis Biotherapeutics appoints CFOmsn.com - April 10 at 8:51 AMArcutis Appoints David Topper as Chief Financial Officerglobenewswire.com - April 10 at 8:00 AMArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 5 at 4:00 PMArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 8%marketbeat.com - April 4 at 2:03 PMArcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.2% marketbeat.com - April 1 at 3:48 PMStock Traders Buy High Volume of Put Options on Arcutis Biotherapeutics (NASDAQ:ARQT)marketbeat.com - April 1 at 12:43 PMSol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Creamfinance.yahoo.com - April 1 at 7:32 AMArcutis to Present at the 23rd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - March 28 at 8:12 AMArcutis to Present at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - March 28 at 8:00 AMArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 2.8%marketbeat.com - March 22 at 12:06 PMArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4.6%marketbeat.com - March 21 at 5:43 PMARQT May 2024 10.000 callfinance.yahoo.com - March 19 at 8:11 PMArcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down to $10.66marketbeat.com - March 18 at 11:25 AMShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Declines By 6.8%marketbeat.com - March 18 at 11:24 AMInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 3,760 Shares of Stockinsidertrades.com - March 16 at 10:59 AMATHA Apr 2024 2.500 putfinance.yahoo.com - March 15 at 11:09 PMArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.2%marketbeat.com - March 13 at 2:58 PMARQT Apr 2024 12.500 callfinance.yahoo.com - March 11 at 11:51 PMARQT Apr 2024 5.000 callfinance.yahoo.com - March 11 at 1:50 PMArcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.7%marketbeat.com - March 11 at 12:44 PMARQT Apr 2024 2.500 callfinance.yahoo.com - March 11 at 8:50 AMArcutis Promotes Todd Tucker to Chief Human Resources Officerglobenewswire.com - March 11 at 8:00 AMArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Brokeragesmarketbeat.com - March 11 at 4:19 AM Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ARQT Media Mentions By Week ARQT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.210.45▲Average Medical News Sentiment ARQT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼64▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ETNB News Today ELVN News Today TNGX News Today ZNTL News Today SAGE News Today IMNM News Today SPRY News Today LBPH News Today OPK News Today ALXO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersYou need to know these two things about AI stocks ASAP…InvestorPlaceThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
